Tvardi Therapeutics, Inc.
TVRD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7,452 | $45,842 | $45,842 | $6,903 |
| - Cash | $37,903 | $22,919 | $21,489 | $13,453 |
| + Debt | $44,448 | $368 | $2,368 | $3,673 |
| Enterprise Value | $13,997 | $23,291 | $26,721 | -$2,877 |
| Revenue | $7,137 | $20,968 | $41,867 | $23,028 |
| % Growth | -66% | -49.9% | 81.8% | – |
| Gross Profit | $6,325 | $14,535 | $34,353 | $21,474 |
| % Margin | 88.6% | 69.3% | 82.1% | 93.3% |
| EBITDA | -$62,600 | -$117,650 | -$83,804 | -$86,887 |
| % Margin | -877.1% | -561.1% | -200.2% | -377.3% |
| Net Income | -$70,867 | -$118,513 | -$85,474 | -$88,441 |
| % Margin | -993% | -565.2% | -204.2% | -384.1% |
| EPS Diluted | -46.59 | -1.85 | -2.2 | -62.77 |
| % Growth | -2,418.4% | 15.9% | 96.5% | – |
| Operating Cash Flow | -$60,917 | -$21,040 | -$17,866 | -$60,087 |
| Capital Expenditures | -$1,046 | -$2,375 | -$50 | -$39 |
| Free Cash Flow | -$61,963 | -$21,040 | -$17,916 | -$60,126 |